Membranous Nephropathy Clinical Trials

13 recruiting

Membranous Nephropathy Trials at a Glance

37 actively recruiting trials for membranous nephropathy are listed on ClinicalTrialsFinder across 6 cities in 28 countries. The largest study group is Phase 2 with 11 trials, with the heaviest enrollment activity in Beijing, Houston, and Atlanta. Lead sponsors running membranous nephropathy studies include University of Michigan, Mario Negri Institute for Pharmacological Research, and First Affiliated Hospital, Sun Yat-Sen University.

Browse membranous nephropathy trials by phase

Treatments under study

About Membranous Nephropathy Clinical Trials

Looking for clinical trials for Membranous Nephropathy? There are currently 13 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Membranous Nephropathy trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Membranous Nephropathy clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 37 trials

Recruiting
Phase 1

A Phase I Clinical Study of Recombinant Humanized Anti-CD20(B-lymphocyte Antigen CD20) Monoclonal Antibody Subcutaneous Injection in the Treatment of Primary Membranous Nephropathy

Primary Membranous Nephropathy
Shanghai Jiaolian Drug Research and Development Co., Ltd52 enrolled6 locationsNCT05668403
Recruiting
Phase 2

A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy

Primary Membranous Nephropathy
Climb Bio, Inc.45 enrolled45 locationsNCT07096843
Recruiting
Phase 2Phase 3

Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)

Primary Membranous Nephropathy
Vertex Pharmaceuticals Incorporated176 enrolled86 locationsNCT07204275
Recruiting
Phase 3

A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)

Primary Membranous Nephropathy
Biogen180 enrolled91 locationsNCT06962800
Recruiting
Phase 2

Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)

Primary Membranous Nephropathy
Alexion Pharmaceuticals, Inc.30 enrolled40 locationsNCT07157787
Recruiting
Phase 4

Efficacy and Safety of Finerenone in Patients With Primary Membranous Nephropathy

Primary Membranous Nephropathy
First Affiliated Hospital, Sun Yat-Sen University116 enrolled1 locationNCT06573411
Recruiting
Phase 2

Study of WAL0921 in Patients With Glomerular Kidney Diseases

Diabetic NephropathiesPrimary Focal Segmental GlomerulosclerosisMinimal Change Disease+2 more
Walden Biosciences96 enrolled50 locationsNCT06466135
Recruiting

An Outcome Analysis of Primary Membranous Nephropathy

Membranous Nephropathy
Mario Negri Institute for Pharmacological Research500 enrolled2 locationsNCT06242327
Recruiting

Autoreactive B Cells in Membranous Nephropathy

Membranous Nephropathy
Mario Negri Institute for Pharmacological Research86 enrolled1 locationNCT04095156
Recruiting
Phase 1Phase 2

A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)

Lupus NephritisPrimary Membranous Nephropathy
Nkarta, Inc.96 enrolled16 locationsNCT06557265
Recruiting
Phase 2

A Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Treatment With AP1189 in Patients With iMN and Severe Proteinuria

Nephrotic Syndrome Due to Idiopathic Membranous NephropathySevere Proteinuria Due to Idiopathic Membranous Nephropathy
SynAct Pharma Aps23 enrolled1 locationNCT04456816
Recruiting
Not Applicable

NEPTUNE Match Study

Nephrotic Syndrome in ChildrenAlport SyndromeFocal Segmental Glomerulosclerosis+6 more
University of Michigan375 enrolled16 locationsNCT04571658
Recruiting
Phase 2

Belimumab With Rituximab for Primary Membranous Nephropathy

Membranous NephropathyNephrotic Syndrome
National Institute of Allergy and Infectious Diseases (NIAID)58 enrolled20 locationsNCT03949855
Recruiting
Phase 4

Rivaroxaban in Idiopathic Membranous Nephropathy

Idiopathic Membranous Nephropathy
Beijing Friendship Hospital134 enrolled1 locationNCT07404436
Recruiting
Early Phase 1

A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in the Treatment of Immune-mediated Kidney Diseases

IgA Nephropathy (IgAN)Membranous NephropathyANCA-associated Vasculitis (AAV)/ANCA-associated Glomerulonephritis (AAGN)+2 more
Grit Biotechnology30 enrolled1 locationNCT07389499
Recruiting
Phase 2

Phase II Randomized, Open-label, Multicenter Clinical Study Evaluating the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of SHR-2173 Injection in Patients With Primary Membranous Nephropathy

Primary Membranous Nephropathy
Guangdong Hengrui Pharmaceutical Co., Ltd75 enrolled1 locationNCT07289763
Recruiting
Phase 3

OBINOTUZUMAB Versus Cyclophosphamide + Glucocorticoids in Primary Membranous Nephropathy(Blossom Study)

Primary Membranous Nephropathy
Huashan Hospital144 enrolled1 locationNCT06781944
Recruiting
Phase 2Phase 3

Obinutuzumab Induced Decreases of PLA2R Antibodies in Membranous Nephropathy: a Pilot Study

Membranous Nephropathy - PLA2R Induced
Radboud University Medical Center20 enrolled1 locationNCT07163611
Recruiting
Phase 1

Safety and Efficacy of CD19 Chimeric Antigen Receptor T-Cell (CAR-T) in the Treatment of Refractory Membranous Nephropathy

Refractory Membranous Nephropathy
The First Affiliated Hospital of Air Force Medicial University5 enrolled1 locationNCT07266181
Recruiting

Interview Study of Adult and Child Patients and Parents of Children With Swelling Due to Nephrotic Syndrome.

EdemaNephrotic Syndrome in ChildrenMembranous Nephropathy+10 more
University of Michigan150 enrolled1 locationNCT05505500